

EFFICACY OF SIMETHICONE PRIOR TO UPPER ENDOSCOPY ON MUCOSAL VISUALIZATION: PRELIMINARY RESULTS OF A BLINDED PROSPECTIVE TRIAL

Maria Luisa Gloria

UEG Week Berlin 2025

Poster

Oesophagus

October 7, 2025

A randomized blinded study of 82 patients found that pre-endoscopic simethicone (100 mg) significantly improved mucosal visibility during EGD compared to placebo, with higher GRACE scores across all upper GI segments and greater endoscopist satisfaction.

KEY POINTS

- Simethicone improved mean GRACE score compared to placebo (7.62 ± 1.7 vs 5.83 ± 1.7 , $p < 0.001$), with significant improvements in esophagus (2.65 vs 2.03 , $p < 0.001$), stomach (2.21 vs 1.63 , $p = 0.002$), and duodenum (2.69 vs 2.17 , $p = 0.001$).
- Median endoscopist satisfaction was higher with simethicone than placebo (8 vs 7 , $p = 0.001$) and strongly correlated with total GRACE score ($r = 0.855$, $p < 0.001$).
- No significant differences were observed in endoscopy duration (7 vs 6 minutes, $p = 0.800$) or diagnostic yield ($p = 0.416$).
- The timing of simethicone administration (median 8 minutes in group A vs 19 minutes in group B) showed very weak correlation with GRACE score ($r = -0.058$, $p = 0.685$).
- Relevant for endoscopists and GI units considering mucosal preparation protocols for upper endoscopy.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/484b51c0-a815-11f0-a4f1-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.